The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Etanercept as Monotherapy in Patients with Psoriasis
Open accessAbstract
BACKGROUND: Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis. METHODS: In this 24-week, double-blind study, 672 patients underwent randomization and 652 either received placebo or received etanercept subcutaneously at a low dose (25 mg once weekly), a medium dose (25 mg twice weekly), or a high dose (50 mg twice weekly). After 12 weeks, patients in the placebo group began twice-weekly treatment with 25 mg of etanercept. The primary measure of clinical response was the psoriasis area-and-severity index. RESULTS: At week 12, there was an improvement from base line of 75 percent or more in the psoriasis area-and-severity index in 4 percent of the patients in the placebo group, as compared with 14 percent of those in the low-dose--etanercept group, 34 percent in the medium-dose--etanercept group, and 49 percent in the high-dose-etanercept group (P<0.001 for all three comparisons with the placebo group). The clinical responses continued to improve with longer treatment. At week 24, there was at least a 75 percent improvement in the psoriasis area-and-severity index in 25 percent of the patients in the low-dose group, 44 percent of those in the medium-dose group, and 59 percent in the high-dose group. The responses as measured by improvements in the psoriasis area-and-severity index were paralleled by improvements in global assessments by physicians and the patients and in quality-of-life measures. Etanercept was generally well tolerated. CONCLUSIONS: The treatment of psoriasis with etanercept led to a significant reduction in the severity of disease over a period of 24 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Self-citationEtanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Krueger, G. G., Koo, J. Y. M., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001) · PubMed · Cited by 969
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U., Romano, P., Mulcahy, L., Dooley, L., Baker, D., & Gottlieb, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04954-0 · Cited by 890
Self-citationThe immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
TNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationPlasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationSchön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationGreb, J. E., Goldminz, A. M., Elder, J. T., Lebwohl, M. G., Gladman, D. D., Wu, J. J., Mehta, N. N., Finlay, A. Y., & Gottlieb, A. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.82 · Cited by 922
Self-citationMease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Etanercept plus Standard Therapy for Wegener's Granulomatosis
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa041884 · Cited by 834
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., & Lebwohl, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062382 · Cited by 807
Self-citationBasra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Van Voorhees, A. S., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 769
Self-citationPathirana, D., Ormerod, A., Saiag, P., Smith, C., Spuls, P., Nast, A., Barker, J., Bos, J., Burmester, G., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 703
Self-citationPapp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060244 · Cited by 680
Alinaghi, F., Calov, M., Kristensen, L. E., Gladman, D. D., Coates, L. C., Jullien, D., Gottlieb, A. B., Gisondi, P., Wu, J. J., Thyssen, J. P., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.027 · Cited by 673
Self-citationTherapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Antoni, C. E., Kavanaugh, A., Kirkham, B., Tutuncu, Z., Burmester, G. R., Schneider, U., Furst, D. E., Molitor, J., Keystone, E., Gladman, D., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20967 · Cited by 640
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800013 · Cited by 593
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Psoriasis assessment tools in clinical trials
Feldman, S. R., & Krueger, G. G. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031237 · Cited by 557
Treatment recommendations for psoriatic arthritis
Ritchlin, C. T., Kavanaugh, A., Gladman, D. D., Mease, P. J., Helliwell, P., Boehncke, W.-H., de Vlam, K., Fiorentino, D., FitzGerald, O., Gottlieb, A. B., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094946 · Cited by 554
Self-citationThaçi, D., Blauvelt, A., Reich, K., Tsai, T.-F., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Hugot, S., You, R., et al. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.05.013 · Cited by 551
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Kim, S.-H., Han, S.-Y., Azam, T., Yoon, D.-Y., & Dinarello, C. A. (2005) · Immunity · doi:10.1016/j.immuni.2004.12.003 · Cited by 535
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Psoriasis pathophysiology: current concepts of pathogenesis
Krueger, J. G., & Bowcock, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031120 · Cited by 523
Gordon, K. B., Langley, R. G., Leonardi, C., Toth, D., Menter, M. A., Kang, S., Heffernan, M., Miller, B., Hamlin, R., Lim, L., et al. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.05.027 · Cited by 510
Self-citationMatching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
Signorovitch, J. E., Sikirica, V., Erder, M. H., Xie, J., Lu, M., Hodgkins, P. S., Betts, K. A., & Wu, E. Q. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.004 · Cited by 505
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
Martin, D. A., Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G., & Russell, C. B. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.194 · Cited by 466
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Nickoloff, B. J., & Nestle, F. O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422147 · Cited by 544
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
Lowes, M. A., Chamian, F., Abello, M. V., Fuentes-Duculan, J., Lin, S.-L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509736102 · Cited by 456
Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed
Dinarello, C. A. (2004) · Journal of Endotoxin Research · doi:10.1179/096805104225006129 · Cited by 435
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Do, G., Hua, C., Mazaud, C., Droitcourt, C., Hughes, C., Ingram, J. R., Naldi, L., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub2 · Cited by 433
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
The Inflammatory Response in Psoriasis: a Comprehensive Review
Deng, Y., Chang, C., & Lu, Q. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8535-x · Cited by 416
Papp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
Current severe psoriasis and the Rule of Tens
Finlay, A. Y. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06502.x · Cited by 394
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
Paller, A. S., Siegfried, E. C., Langley, R. G., Gottlieb, A. B., Pariser, D., Landells, I., Hebert, A. A., Eichenfield, L. F., Patel, V., Creamer, K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa066886 · Cited by 391
Self-citationSignorovitch, J. E., Wu, E. Q., Yu, A. P., Gerrits, C. M., Kantor, E., Bao, Y., Gupta, S. R., & Mulani, P. M. (2010) · PharmacoEconomics · doi:10.2165/11538370-000000000-00000 · Cited by 377
Psoriasis: a possible risk factor for development of coronary artery calcification
Ludwig, R. J., Herzog, C., Rostock, A., Ochsendorf, F. R., Zollner, T. M., Thaci, D., Kaufmann, R., Vogl, T. J., & Boehncke, W.-H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07562.x · Cited by 374
TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques
Gottlieb, A. B., Chamian, F., Masud, S., Cardinale, I., Abello, M. V., Lowes, M. A., Chen, F., Magliocco, M., & Krueger, J. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2721 · Cited by 372
Self-citationTreatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Mattei, P. L., Corey, K. C., & Kimball, A. B. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12106 · Cited by 358
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Leoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Kuek, A., Hazleman, B. L., & Östör, A. J. K. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052688 · Cited by 335
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.719 · Cited by 324
Self-citationCurrent and future management of psoriasis
Menter, A., & Griffiths, C. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61129-5 · Cited by 321
Conrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Di Meglio, P., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 317
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14433 · Cited by 313
Ko, J. M., Gottlieb, A. B., & Kerbleski, J. F. (2009) · Journal of Dermatological Treatment · doi:10.1080/09546630802441234 · Cited by 313
Self-citationKeratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases
Siebert, S., Tsoukas, A., Robertson, J., & McInnes, I. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009639 · Cited by 307
Wu, J. J., Poon, K.-Y. T., Channual, J. C., & Shen, A. Y.-J. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.2502 · Cited by 304
Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis
Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., Betts, K. A., & Augustin, M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.4029 · Cited by 294
Autoimmunity through Cytokine-Induced Dendritic Cell Activation
Banchereau, J., Pascual, V., & Palucka, A. K. (2004) · Immunity · doi:10.1016/s1074-7613(04)00108-6 · Cited by 293
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Self-citationLew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Kauffman, C. L., Aria, N., Toichi, E., McCormick, T. S., Cooper, K. D., Gottlieb, A. B., Everitt, D. E., Frederick, B., Zhu, Y., Graham, M. A., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23448.x · Cited by 279
Self-citationWang, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27180 · Cited by 276
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D., Finlay, A. Y., Grifitths, C. E. M., Jackson, K., McHugh, N. J., et al. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06893.x · Cited by 275
S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update
Nast, A., Boehncke, W., Mrowietz, U., Ockenfels, H., Philipp, S., Reich, K., Rosenbach, T., Sammain, A., Schlaeger, M., Sebastian, M., et al. (2012) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07919.x · Cited by 272
Mease, P. J., & Armstrong, A. W. (2014) · Drugs · doi:10.1007/s40265-014-0191-y · Cited by 271
Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H., & Elder, J. T. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700807 · Cited by 266
Langley, R. G. B., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.865009 · Cited by 264
Papp, K. A., Menter, M. A., Raman, M., Disch, D., Schlichting, D. E., Gaich, C., Macias, W., Zhang, X., & Janes, J. M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14403 · Cited by 263
Cho, J. H., & Feldman, M. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 260
Averting inflammation by targeting the cytokine environment
Kopf, M., Bachmann, M. F., & Marsland, B. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2805 · Cited by 257
Psoralen and Ultraviolet A Light Therapy for Psoriasis
Stern, R. S. (2007) · New England Journal of Medicine · doi:10.1056/nejmct072317 · Cited by 149
IκBζ is a key driver in the development of psoriasis
Johansen, C., Mose, M., Ommen, P., Bertelsen, T., Vinter, H., Hailfinger, S., Lorscheid, S., Schulze-Osthoff, K., & Iversen, L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509971112 · Cited by 125
Kimball, A. B., Leonardi, C., Stahle, M., Gulliver, W., Chevrier, M., Fakharzadeh, S., Goyal, K., Calabro, S., Langholff, W., Menter, A., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13013 · Cited by 117
Self-citationEffectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial
Armstrong, A. W., Chambers, C. J., Maverakis, E., Cheng, M. Y., Dunnick, C. A., Chren, M.-M., Gelfand, J. M., Wong, D. J., Gibbons, B. M., Gibbons, C. M., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3062 · Cited by 103
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
Short- and long-term effects of IL-1 and TNF antagonists on periodontal wound healing
Zhang, X., Kohli, M., Zhou, Q., Graves, D. T., & Amar, S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3514 · Cited by 71
Psoriasis and Depression: The Role of Inflammation
González-Parra, S., & Daudén, E. (2019) · Actas Dermo-Sifiliográficas (English Edition) · doi:10.1016/j.adengl.2018.05.035 · Cited by 70
Wan, J., Abuabara, K., Troxel, A. B., Shin, D. B., Van Voorhees, A. S., Bebo, B. F., Krueger, G. G., Callis Duffin, K., & Gelfand, J. M. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.03.012 · Cited by 41
McTiernan, C. F., Mathier, M. A., Zhu, X., Xiao, X., Klein, E., Swan, C. H., Mehdi, H., Gibson, G., Trichel, A. M., Glorioso, J. C., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303020 · Cited by 40
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-20
- Volume
- 349
- Issue
- 21
- Pages
- 2014-2022
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2091442391
- Cited by
- 1,175
- References
- 20
- FWCI
- 26.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.